Abstract 1699P
Background
The composition of the gut microbiome can impact outcomes with ICIs (Routy et al Science 2018) and Latinos with mRCC have a different gut microbiome composition than their non-Latino counterparts (Barragan-Carrillo et al ASCO 2024). Two trials provided evidence that CBM588, a live biotherapeutic, improved outcomes in pts with mRCC on ICI (Dizman et al Nat Med 2022; Ebrahimi et al ASCO 2023). Herein we analyze the impact of CBM588 on the gut microbiome and clinical outcome between Latino and non-Latino pts with mRCC.
Methods
We analyzed stool samples from two phase I trials that enrolled pts with mRCC treated with frontline nivolumab/ipilimumab or nivolumab/cabozantinib +/- CBM588. Pts were dichotomized into Latino and non-Latino groups. Stool specimens were collected at week 12 of treatment. Whole metagenomic sequencing was performed on stool specimens. ANCOM-BC analysis was used to identify differences in the relative abundance of bacterial species (spp) between groups. α-diversity was evaluated using the Shannon diversity index, and β-diversity was assessed using the Bray-Curtis and Jaccard dissimilarity measures.
Results
Among 59 pts with mRCC, 27 were Latino and 32 non-Latino. Median age was 60, most had clear cell histology (88%) and intermediate/poor risk disease (79%). Randomization to CBM588 was balanced between Latino and non-Latino patients (59% v 71%, respectively; P=0.30). Disease control rate (DCR) in Latino pts treated with CBM588 was higher than in non-Latino pts (100% vs. 70%, P=0.01). In the CBM588 group, enrichment of 6 bacterial spp and depletion in 8 spp was observed in Latino pts. The gut microbiome of Latino pts was enriched by spp associated with ICI benefit (p≤.05), including Roseburia faecis (LFC 2.4) and Roseburia spp AF02 12 (LFC 1.93). We saw no difference in α and β diversity between Latinos and non-Latinos, with and without CBM588.
Conclusions
Latino pts who received ICI with CBM588 had a higher DCR as compared to non-Latino pts. Additionally, they exhibited increased bacterial spp linked to favorable outcomes with ICIs. Our findings suggest that trials aimed at modulating the microbiome could have unique value in minority populations.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
City of Hope Comprehensive Cancer Center.
Funding
Has not received any funding.
Disclosure
A. Chehrazi-Raffle: Financial Interests, Personal, Advisory Board: Exelixis, Inc, Aveo Inc., Pfizer Inc.; Financial Interests, Personal, Invited Speaker: Exelixis, Inc, OncLive/MJH Life Sciences, ASCO Direct. S.K. Pal: Financial Interests, Institutional, Local PI: Eisai, Genentech, Roche, Exelixis, Pfizer, CRISPR Therapeutics, Allogene Therapeutics, Xencor, Novartis; Non-Financial Interests, Member: ASCO; Non-Financial Interests, Leadership Role: SWOG; Other, Travel reimbursement: CRISPR, Roche. All other authors have declared no conflicts of interest.
Resources from the same session
1676P - Sexuality among Tunisian breast cancer survivors
Presenter: Nefzi Issaad
Session: Poster session 11
1677P - Sexual health among men receiving chemotherapy: A double burden or a haven?
Presenter: Yosra Berrazaga
Session: Poster session 11
1678P - Tunisian couples confronted with breast cancer
Presenter: Malek Khlif
Session: Poster session 11
1679P - Self-reported cancer-related cognitive impairment (CRCI) in early breast cancer among Egyptian women: Is disease biology the key?
Presenter: Rowan Ibrahim
Session: Poster session 11
1680P - Factors mediating the association between adverse life experiences and pain in patients with localized breast cancer
Presenter: Ayelet Shai
Session: Poster session 11
1681P - Evaluation of sleep disturbance in cancer patients: A cross-sectional study
Presenter: Ines Lajnef
Session: Poster session 11
1682P - Assessment of health-related quality of life, psychosocial distress and financial toxicity among prostate cancer patients in luth: A cross-sectional survey in south-west Nigeria
Presenter: Rasaq Jimoh
Session: Poster session 11
1683P - Self-care confidence as a predictor of symptom burden and quality of life in people living with myeloproliferative neoplasms
Presenter: Valentina Biagioli
Session: Poster session 11
1684P - Insights into the daily lives and perceptions of cancer survivors: What hides beyond survival?
Presenter: Haifa Rachdi
Session: Poster session 11
1685P - A comprehensive approach to integrating family caregivers as partners in outpatient cancer care in Germany
Presenter: Petya Zyumbileva
Session: Poster session 11